CIK 0000876343 · Non-accelerated filer<br>Smaller reporting company
Lineage Cell Therapeutics, Inc.
Sign in to watch- Ticker
- LCTX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 943127919
- Phone
- 5105213390
- Business address
- 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008
- Former names
- BIOTIME INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-31 | Culley Brian M President and CEO | Purchase | +6,400 | $1.53 | $10K | 97,787 |
| 2022-03-31 | Culley Brian M President and CEO | Option exercise · Restricted Stock Units | −15,450 | 15,450 | ||
| 2022-03-28 | Amin Dipti Director | Purchase | +35,000 | $1.63 | $57K | 35,000 |
| 2022-03-25 | Culley Brian M President and CEO | Purchase | +5,250 | $1.38 | $7K | 81,280 |
| 2022-03-25 | BROADWOOD PARTNERS, L.P. Director | Purchase | +470,000 | $1.44 | $678K | 34,935,485 |
| 2022-03-25 | BROADWOOD PARTNERS, L.P. Director | Purchase | +0 | 34,935,485 | ||
| 2022-03-24 | Mulroy Michael H. Director | Purchase | +7,000 | $1.40 | $10K | 258,555 |
| 2022-03-24 | BROADWOOD PARTNERS, L.P. Director | Purchase | +200,000 | $1.42 | $284K | 34,465,485 |
| 2022-03-24 | BROADWOOD PARTNERS, L.P. Director | Purchase | +0 | 34,465,485 | ||
| 2022-03-23 | BROADWOOD PARTNERS, L.P. Director | Purchase | +260,106 | $1.37 | $355K | 34,265,485 |
| 2022-03-23 | BROADWOOD PARTNERS, L.P. Director | Purchase | +0 | 34,265,485 | ||
| 2022-03-10 | Culley Brian M President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +1,250,000 | 1,250,000 | ||
| 2022-03-10 | Culley Brian M President and CEO | Grant or award · Restricted Stock Units | +300,000 | 300,000 | ||
| 2022-03-10 | Samuel George A. III General Counsel/Secretary | Grant or award · Employee Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2022-03-10 | Hogge Gary S. SVP,Clinical & Medical Affairs | Grant or award · Employee Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2022-03-10 | Cook Kevin Leon Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2022-02-11 | Samuel George A. III General Counsel/Secretary | Grant or award · Restricted Stock Units | +24,303 | 24,303 | ||
| 2022-02-11 | Hogge Gary S. SVP,Clinical & Medical Affairs | Grant or award · Restricted Stock Units | +52,081 | 52,081 | ||
| 2022-02-11 | Cook Kevin Leon Chief Financial Officer | Grant or award · Restricted Stock Units | +13,888 | 13,888 | ||
| 2022-02-11 | Culley Brian M President and CEO | Grant or award · Restricted Stock Units | +124,997 | 124,997 |
Page 6 of 8 · 153 trades